Payment overview · 2025
General Payments
$497.58
27 reported records · 13 companies
Healthcare provider profile · identity verified
Paul Blakely Scaddan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SEBEWAING, MI · NPI 1912944737
Verified facts
What the public records show
CMS Open Payments records show Paul Blakely Scaddan, M.D. received $497.58 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.62 | 30.1% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.07 | 11.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.83 | 10.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.61 | 8.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $36.50 | 7.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.08 | 7.2% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $24.05 | 4.8% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $18.79 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.68 | 3.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.43 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.97 | 3.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.63 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.32 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $497.58 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.18 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.18 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.07 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.78 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 183 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
43 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 108 |
| Omeprazole | Omeprazole | 411 | 124 |
| Losartan Potassium | Losartan Potassium | 396 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 315 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 78 |
| Metformin Hcl | Metformin Hcl | 256 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 81 |
| Lisinopril | Lisinopril | 220 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 71 |
| Potassium Chloride | Potassium Chloride | 195 | 56 |
| Gabapentin | Gabapentin | 186 | 60 |
| Eliquis | Apixaban | 183 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 48 |
| Simvastatin | Simvastatin | 161 | 39 |
| Allopurinol | Allopurinol | 159 | 47 |
| Tramadol Hcl | Tramadol Hcl | 147 | 50 |
| Furosemide | Furosemide | 133 | 54 |
| Alprazolam | Alprazolam | 132 | 52 |
| Enalapril Maleate | Enalapril Maleate | 120 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 120 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 36 |
| Ozempic | Semaglutide | 117 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 32 |
| Carvedilol | Carvedilol | 105 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 38 |
| Jardiance | Empagliflozin | 79 | 18 |
| Famotidine | Famotidine | 76 | 27 |
| Spironolactone | Spironolactone | 76 | 22 |
| Sertraline Hcl | Sertraline Hcl | 75 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 19 |
| Meloxicam | Meloxicam | 65 | 22 |
| Celecoxib | Celecoxib | 64 | 17 |
| Lovastatin | Lovastatin | 64 | 19 |
| Buspirone Hcl | Buspirone Hcl | 63 | 23 |
| Atenolol | Atenolol | 60 | 19 |
| Ezetimibe | Ezetimibe | 60 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 20 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 22 |
| Glipizide Er | Glipizide | 58 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 18 |
| Bumetanide | Bumetanide | 56 | 18 |
| Warfarin Sodium | Warfarin Sodium | 55 | 15 |
| Clonazepam | Clonazepam | 53 | 14 |
| Telmisartan | Telmisartan | 52 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 16 |
| Fenofibrate | Fenofibrate | 47 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Cephalexin | Cephalexin | 46 | 27 |
| Xarelto | Rivaroxaban | 46 | 15 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 43 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 14 |
| Sucralfate | Sucralfate | 39 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 37 | 36 |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 18 |
| Lorazepam | Lorazepam | 34 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Prednisone | Prednisone | 30 | 21 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 27 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Naproxen | Naproxen | 27 | 13 |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 26 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Finasteride | Finasteride | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 11 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $497.58 · 27 records | Novo Nordisk Inc | ABILIFY MAINTENA, Auvelity, Cologuard Collection Kit, DUROLANE, ELIQUIS, INSPIRE, OTEZLA, Ohtuvayre, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error